Skip to main content

Quantitative MRI of Prostate Cancer as a Biomarker and Guide for Treatment

By Fiona Fennessy1, Andriy Fedorov1, Robert Mulkern1, Michelle Hirsch2, Mary-Ellen Paplin3, Sandeep Gupta4, Clair Beard5

1. Radiology, BWH 2. Pathology, BWH 3. Oncology, DFCI 4. General electric Global Research 5. Radiation Oncology, BWH

Download (PPT)

Licensed under

Published on


Prostate cancer (PCa) remains the most common malignancy and third leading cause of cancer-related mortality in American men with incidence estimated at >450,000 cases per year by 2015. The natural history of PCa is remarkably heterogeneous and still not completely understood. The need for an accurate non-invasice imaging tool increases as the number of men with localized disease increases. With the recent advances in multiparametric MRI (mpMRI) [1], there is a hope that the various MR imaging markers, such as Apparent Diffusion Coefficient (ADC) derived from Diffusion Weighted (DWI) MRI and Dynamic Contrast Enhanced MRI (DCE-MRI) can be applied for PCa localization and grading [2], and in the evaluation of the response to treatment [1].

Cite this work

Researchers should cite this work as follows:

  • Fiona Fennessy; Andriy Fedorov; Robert Mulkern; Michelle Hirsch; Mary-Ellen Paplin; Sandeep Gupta; Clair Beard (2014), "Quantitative MRI of Prostate Cancer as a Biomarker and Guide for Treatment,"

    BibTex | EndNote